Logo

GSK's Nucala Receives Health Canada's Approval for Severe Eosinophilic Asthma in Children and Adolescents

Share this

GSK's Nucala Receives Health Canada's Approval for Severe Eosinophilic Asthma in Children and Adolescents

Shots:

  • Nucala (mepolizumab) has received Health Canada’s approval as an add-on maintenance therapy for adolescents & children aged ≥6yrs. with SEA
  •  The extension of NUCALA's indication for adolescents and children aged ≥6yrs. allow the company to bring the therapy to patients and their families with limited treatment options
  • Nucala is the first IL5 biologic to be approved for SAE in a pediatric population (as young as 6 yrs. old) in Canada. The therapy has received approval in 20+ markets- including the US & EU for adult patients with SAE and indicated as an approved therapy for pediatric use in patients aged 6-17yrs. as an add-on treatment for SAE

Click here ­to­ read full press release/ article 

 Ref: Canada Newswire | Image: GSK


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions